

CT·RS

Cell Therapies Research & Services



Because every patient has the right to expect treatment

CTRS, Cell Therapies research & Services, is a French pharmaceutical company with a strong international dimension. Since our creation, we are committed to developing and commercializing treatments for patients with strong unmet medical needs.

Our main focus is rare diseases. Guided by science and research, our ambition is to serve as a link between academic research program and patients. Thus, we work hand-by-hand with academic structures to develop partnership for relieving and curing patients with rare and severe disorders.





Projects in
partnerships



People



Awards

*Galien French and International awards, « Pilule d'Or » of Prescrire,
Twice honored firm with Prescrire's information awards*



CTRS always worked in close collaboration with academic institutions. In more than 15 years, our numerous partnerships have made it possible to offer patients the most appropriate diagnostic and therapeutic solutions for their needs.

Our mission

Bring innovative, effective and safe treatments to rare or ultra-rare diseases patients where unmet need is high

Our values

- Find solutions that will give patients access to treatment
- Seamless teamwork to serve health professionals, our partners and especially patients
- Be responsive and flexible
- Provide responsible medical information



Establishment of Laboratoires CTRS

CTRS selected by AP-HP for the commercialisation of dexamethasone (Neofordex®)

Galien and Prescrire's Gold Pill Awards for Orphacol®
Firm honored with Prescrire's information award

Marketing authorization for Dexliq® in 12 countries



2002

2007

2010

2013

2014

2016

2017

2018

2020

2021

Partnership with AP-HP for the development of cholic acid (Orphacol®)

European marketing authorization for Orphacol®

European marketing authorization for Neofordex®
International Galien Award for Orphacol®

Partnership with AP-HP for the development of CTRS-CC2

Partnership with Inserm and Institut Imagine for the development of CTRS-CC1
Collaboration with Neomedlight for commercialisation of CareMin 650™ in France
Backed by Mérieux Equity Partners
Growth Champions from Les Echos (leading French business newspaper)



Management Team



Antoine Ferry, MD
Chief Executive Officer



Philippe Maret, PharmD
Qualified Person
Managing Director



Sabrina Belkadi
Finance and Administration
Director



Bernard Deschamps, MBA
Co-Founder
Managing Director



Marco Liguori, MBA
Commercial Operation and
Business Development Director
Managing Director



Marie Fey
Regulatory Affairs Director



Christophe Pompon, PharmD
Medical Affairs Director




Virginija Bambalaite, MD
Medical Director



Mathieu Robain, MD, PhD
Head of Medical Data



Portfolio

PRODUCT	THERAPEUTIC AREA	INDICATION	STATUS
Orphacol® Cholic acid	Digestive system diseases, metabolism, inborn errors	Treatment of 2 inborn errors of primary bile acid synthesis	Marketed EU MA Sept 2013
Neofordex® Dexamethasone <i>tablet</i>	Hematology	Treatment of symptomatic multiple myeloma in adults in combination with other agents	Marketed EU MA Mar 2016
CareMin 650™ Medical device 	Oncology	Treatment of radio- or chemo-induced mucositis and dermatitis	Marketed CE mark Feb 2020
CTRS-CC1	Dermatology	Treatment of Olmsted syndrome (palmoplantar keratoderma)	Clinical stage
CTRS-CC2	Fertility	Increased probability of success in In Vitro Fertilization	Clinical stage
Dexliq® Dexamethasone <i>solution</i>	Oncology	Included treatment of symptomatic multiple myeloma in combination with other medicinal products	MAs 2018 On going




Our partnership policy is a cornerstone of our success story and overall strong growth.

Always looking for new and value-added partnerships, we are convinced that it's by pooling our skills that we will be able to develop and bring to market new therapeutic solutions for patients.

Our single-minded focus is on diseases affecting small patient populations in which current standard of care is not satisfactory. We encourage you to contact us to discuss potential collaborations.

CT·RS

Cell Therapies Research & Services

 63 rue de l'est
92100 Boulogne-Billancourt
FRANCE

 +33 (0)1 41 22 09 70

 ctrs@ctrs.fr

 www.ctrs.fr